[1] Damm, F., Heuser, M., Morgan, M., Wagner, K., Gorlich, K., et al. (2011) Integrative Prognostic Risk Score in Acute Myeloid Leukemia with Normal Karyotype. Blood, 117, 4561-4568.
http://dx.doi.org/10.1182/blood-2010-08-303479
[2] Pollanen, J., Stephens, R.W. and Vaheri, A. (1991) Directed Plasminogen Activation at the Surface of Normal and Malignant Cells. Advances in Cancer Research, 57, 273-328.
http://dx.doi.org/10.1016/S0065-230X(08)61002-7
[3] Behrendt, N. and Stephens, R.W. (1998) The Urokinase Receptor. Fibrinolysis Proteolysis, 12, 191-204.
[4] Blasi, F. (1997) uPA, uPAR, PAI-1: Key Intersection of Proteolytic, Adhesive and Chemotactic Highways? Immunology Today, 18, 415-417.
http://dx.doi.org/10.1016/S0167-5699(97)01121-3
[5] Aguirre-Ghiso, J.A., Kovalski, K. and Ossowski, L. (1999) Tumor Dormancy Induced by Downregulation of Urokinase Receptor in Human Carcinoma Involves Integrin and MAPK Signaling. The Journal of Cell Biology, 147, 89-103.
http://dx.doi.org/10.1083/jcb.147.1.89
[6] Chapman, H.A. (1997) Plasminogen Activators, Integrins, and the Coordinated Regulation of Cell Adhesion and Migration. Current Opinion in Cell Biology, 9, 714-724.
http://dx.doi.org/10.1016/S0955-0674(97)80126-3
[7] Gyetko, M.R., Todd, R.F., Wilkinson, C.C. and Sitrin, R.G. (1994) The Urokinase Receptor Is Required for Human Monocyte Chemotaxis in Vitro. The Journal of Clinical Investigation, 93, 1380-1387.
http://dx.doi.org/10.1172/JCI117114
[8] Almeida, J. (1999) Extensive Characterization of the Immunophenotype and Pattern of Cytokine Production by Distinct Subpopulation of Normal Human Peripheral Blood MHC + Lineage Cells. Clinical & Experimental Immunology, 188, 392-409.
http://dx.doi.org/10.1046/j.1365-2249.1999.01078.x
[9] Plesner, T., Ralfkiaer, E., Wittrup, M., Ferrero, E., Bondanza, A., et al. (1994) Expression of the Receptor for Urokinase-Type Plasminogen Activator in Normal and Neoplastic Blood Cells and Hemopoietic Tissue. American Journal of Clinical Pathology, 102, 835-841.
[10] Ramage, J.G., Vallera, D.A., Black, J.H., Aplan, P.D., Kees, U.R., et al. (2003) The Diphtheria Toxin/Urokinase Fusion Protein (DTAT) Is Selectively Toxic to CD87 Expressing Leukemic Cells. Leukemia Research, 27, 79-84.
http://dx.doi.org/10.1016/S0145-2126(02)00077-2
[11] Schlossman, S., Boumsell, L., Gilks, W., Harlan, J.M., Kishimoto, T., Morimoto, C., Ritz, J., Shaw, S. and Silverstein, R. (1995) Leucocyte Typing V: White Cell Differentiation Antigens. Oxford University Press, New York.
[12] de Bock, C.E., Lin, Z., Itoh, T., Morris, D., Murrell, G. and Wang, Y. (2005) Inhibition of Urokinase Receptor Gene Expression and Cell Invasion by Anti-uPAR DNAzymes in Osteosarcoma Cells. FEBS Journal, 272, 3572-3582.
http://dx.doi.org/10.1111/j.1742-4658.2005.04778.x
[13] Han, B., Nakamura, M., Zhou, G.Y., Ishii, A., Nakamura, A., Bai, Y.H., et al. (2006) Calcitonin Inhibits Invasion of Breast Cancer Cells: Involvement of Urokinase-Type Plasminogen Activator (UPA) and uPA Receptor. International Journal of Oncology, 28, 807-814.
http://dx.doi.org/10.3892/ijo.28.4.807
[14] Bene, M.C., Castoldi, G., Knapp, W., Rigolin, G.M., Escribano, L., Lemez, P., et al. (2004) CD87 (Urokinase-Type Plasminogen Activator Receptor), Function and Pathology in Hematological Disorders: A Review. Leukemia, 18, 394-400.
[15] Graf, M., Reif, S., Hecht, K., Pelka-Fleischer, R., Pfister, K. and Schmetzer, H. (2005) High Expression of Urokinase Plasminogen Activator Receptor (UPA-R) in Acute Myeloid Leukemia (AML) Is Associated with Worse Prognosis. American Journal of Hematology, 79, 26-35.
http://dx.doi.org/10.1002/ajh.20337
[16] Lanza, F., Matutes, E., Orfao, A., Knapp, W., Bene, M.C., et al. (1998) Expression and Functional Role of Urokinase-Type Plasminogen Activator Receptor in Normal and Acute Leukemic Cells. British Journal of Haematology, 103, 110-123.
http://dx.doi.org/10.1046/j.1365-2141.1998.00932.x
[17] Atfy, M., Eissa, M., Salah, H.E. and El Shabrawy, D.A. (2012) Role of Urokinase Plasminogen Activator Receptor (CD87) as a Prognostic Marker in Acute Myeloid Leukemia. Medical Oncology, 29, 2063-2069.
http://dx.doi.org/10.1007/s12032-011-9993-x
[18] Knapp, W., Strobl, H. and Majdic, O. (1994) Flow Cytometric Analysis of Cell Surface and Intracellular Antigens in Leukemia Diagnosis. Cytometry, 18, 187-198.
http://dx.doi.org/10.1002/cyto.990180402
[19] Aref, S., El-Sherbiny, M., Mabed, M., Menessy, A. and El-Rafaei, M. (2003) Urokinase Plasminogen Activator Receptor and Soluble Matrix Metalloproteinase 9 in Acute Myeloid Leukemia Patients: A Possible Relation to Disease Invasion. Hematology, 8, 385-391.
http://dx.doi.org/10.1080/10245330310001621323
[20] Nadir, Y., Katz, T., Sarig, G., Hoffman, R., Oliven, A., Rowe, J.M., et al. (2005) Hemoststic Balance on the Surface of Leukemic Cells: The Role of Tissue Factor and Urokinase Plasmiongen Activator Receptor. Haematologica, 90, 1549-1556.
[21] Scherrer, A., Wohlwend, A., Kruithof, E.K.O., Vassalli, J.-D. and Sappino, A.-P. (1999) Plasminogen Activation in Human Acute Leukaemias. British Journal of Haematology, 105, 920-927.
http://dx.doi.org/10.1046/j.1365-2141.1999.01432.x
[22] Plesner, T., Ralfkiaer, E., Wittrup, M., Johnsen, H., Pyke, C., Pedersen, T.L., et al. (1994) Expression of the Receptor for Urokinase-Type Plasminogen Activator in Normal and Neoplastic Blood Cells and Hemopoietic Tissue. American Journal of Clinical Pathology, 102, 835-884.
[23] Jardi, M., Ingles-Esteve, J., Burgal, M., Azqueta, C., Velsaco, F., López-Pedrera, C., et al. (1996) Distinct Patterns of Urokinase Receptor (uPAR) Expression by Leukemic Cells and Peripheral Blood Cells. Thrombosis and Haemostasis, 76, 1009-1019.
[24] Rigolin, G.M., Tieghi, A., Ciccone, M., Bragotti, L.Z., Cavazzini, F., Della Porta, M., et al. (2003) Soluble Urokinasetype Plasminogen Activator Receptor (suPAR) as an Independent Factor Predicting Worse Prognosis and Extra-Bone Marrow Involvement in Multiple Myeloma Patients. British Journal of Haematology, 120, 953-959.
http://dx.doi.org/10.1046/j.1365-2141.2003.04176.x
[25] Sawai, H., Okada, Y., Funahashi, H., Matsuo, Y., Takahashi, H., Takeyama, H. and Manabe, T. (2006) Interleukin-1α Enhances the Aggressive Behavior of Pancreatic Cancer Cells by Regulating the α6β1-Integrin and Urokinase Plasminogen Activator Receptor Expression. BMC Cell Biology, 7, 8.